Skip to main content
Clinical Trials/CTIS2023-505143-39-00
CTIS2023-505143-39-00
Recruiting
Phase 1

Short-term changes in cardiovascular risk determinants after temporarily stopping gender-affirming hormone therapy in older transgender women - a pilot study - NL81591.018.22

Amsterdam UMC0 sites30 target enrollmentJune 28, 2023

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Transgender women using long-term gender-affirming hormone therapy
Sponsor
Amsterdam UMC
Enrollment
30
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 28, 2023
End Date
TBD
Last Updated
last year
Study Type
Interventional clinical trial of medicinal product

Investigators

Sponsor
Amsterdam UMC

Eligibility Criteria

Inclusion Criteria

  • Age \> 54 years, Use of gender\-affirming hormone therapy (GHT) for at least 10 years, Current use of GHT, Currently in treatment at the Center of Expertise on Gender Dysphoria: last clinical appointment \<3 years ago, Undergone gonadectomy (i.e., vaginoplasty or orchiectomy)

Exclusion Criteria

  • Insufficient understanding of the Dutch language

Outcomes

Primary Outcomes

Not specified

Similar Trials